Issues related to drug pricing proposals; Issues related to Rx oversight; Issues related to PBM oversight; Issues related to budget reconciliation; Issues related to Most Favored Nation proposals.
2026 · 1st Quarter (Jan 1 - Mar 31)
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Filed by AKIN GUMP STRAUSS HAUER & FELD.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 20, 2026
- Income
- $120,000.00
- Expenses
- Not reported
- Registrant
- AKIN GUMP STRAUSS HAUER & FELD
- Filing UUID
- 870af238-3005-49d0-ac98-013cba447d85
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to IP protection; Issues related to market access; Issues related to PhRMA Section 232 tariffs.
Issues related to patent reform legislation; Issues related to H.R. 3160/S. 1553 - PREVAIL Act.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.